相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study
Jae-Weon Kim et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2015)
State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer
Whitney Graybill et al.
GYNECOLOGIC ONCOLOGY (2015)
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia
H. Hirte et al.
GYNECOLOGIC ONCOLOGY (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Value-Based Cancer Care
Robert C. Young
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
Francesca De Felice et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
Alison Backen et al.
CLINICAL CANCER RESEARCH (2014)
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu et al.
LANCET ONCOLOGY (2014)
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2013)
Incidence and management of edema associated with trebananib (AMG 386)
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2013)
Latest research and treatment of advanced-stage epithelial ovarian cancer
Robert L. Coleman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
E. Dean et al.
BRITISH JOURNAL OF CANCER (2012)
Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
Paul Nathan et al.
CLINICAL CANCER RESEARCH (2012)
Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study
Dana M. Chase et al.
GYNECOLOGIC ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
VEGF Inhibition, Hypertension, and Renal Toxicity
Suzanne R. Hayman et al.
CURRENT ONCOLOGY REPORTS (2012)
At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
David E. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
Ernest S. Han et al.
GYNECOLOGIC ONCOLOGY (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2008)
Oxidative stress regulates expression of VEGFR1 in myeloid cells:: Link to tumor-induced immune suppression in renal cell carcinoma
Sergei Kusmartsev et al.
JOURNAL OF IMMUNOLOGY (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2006)
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
BJ Monk et al.
GYNECOLOGIC ONCOLOGY (2005)
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
AN Gordon et al.
GYNECOLOGIC ONCOLOGY (2004)
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
WT Huinink et al.
ANNALS OF ONCOLOGY (2004)
分享论文
